Xiang Qin Selected Research

siltuximab

1/2019	Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma.
10/2015	A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
5/2015	Dose selection of siltuximab for multicentric Castleman's disease.
6/2014	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.
7/2013	A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
6/2013	A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.
5/2013	A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
8/2010	Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiang Qin Research Topics

Disease

39	Neoplasms (Cancer) 10/2022 - 01/2014
19	Multiple Myeloma 10/2022 - 05/2013
8	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2018
5	Infections 10/2021 - 05/2013
4	Thrombocytopenia (Thrombopenia) 01/2020 - 07/2013
4	Neutropenia 01/2020 - 07/2013
3	Amyloidosis 01/2022 - 01/2021
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2021 - 06/2021
3	Neoplasm Metastasis (Metastasis) 01/2021 - 09/2017
3	COVID-19 01/2021 - 07/2020
3	Disease Progression 01/2020 - 10/2016
3	Anemia 10/2016 - 07/2013
3	Castleman Disease (Castleman's Disease) 10/2015 - 08/2010
2	Colorectal Neoplasms (Colorectal Cancer) 07/2022 - 11/2021
2	Triple Negative Breast Neoplasms 01/2022 - 01/2020
2	Liver Neoplasms (Liver Cancer) 10/2021 - 01/2021
2	Immunoglobulin Light-chain Amyloidosis 01/2021 - 01/2020
2	Pain (Aches) 01/2021 - 10/2015
2	Lymphopenia (Lymphocytopenia) 01/2021 - 10/2015
2	Residual Neoplasm 01/2021 - 10/2016
2	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 10/2016 - 03/2015
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 10/2015 - 08/2010
2	Hypercholesterolemia 10/2015 - 07/2013
2	Hypertriglyceridemia 10/2015 - 07/2013
2	Leukopenia 10/2015 - 07/2013
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 05/2015 - 07/2013
2	Inflammation (Inflammations) 03/2014 - 01/2013
1	Hematuria 06/2022
1	Leukemia 04/2022
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 04/2022
1	Hyperthermia 10/2021

Drug/Important Bio-Agent (IBA)

16	daratumumabIBA 10/2022 - 08/2016
14	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 05/2013
11	Bortezomib (Velcade)FDA Link 01/2022 - 05/2013
10	Pharmaceutical PreparationsIBA 04/2022 - 07/2013
8	siltuximabIBA 01/2019 - 08/2010
7	Interleukin-6 (Interleukin 6)IBA 01/2019 - 08/2010
7	Monoclonal AntibodiesIBA 08/2016 - 08/2010
6	Lenalidomide (CC 5013)FDA Link 01/2021 - 10/2016
5	Therapeutic UsesIBA 03/2022 - 03/2015
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2018
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 01/2020
4	OligonucleotidesIBA 01/2021 - 01/2019
3	IntegrinsIBA 01/2020 - 07/2018
2	OvalbuminIBA 10/2022 - 03/2014
2	MicellesIBA 10/2022 - 11/2019
2	Lovastatin (Mevacor)FDA LinkGeneric 07/2022 - 11/2021
2	Deoxyglucose (2 Deoxy D glucose)IBA 07/2022 - 11/2021
2	Glutathione (Reduced Glutathione)IBA 03/2022 - 01/2021
2	1-phenyl-3,3-dimethyltriazene (PDT)IBA 03/2022 - 03/2018
2	Biological ProductsIBA 01/2022 - 01/2021
2	polyacrylamideIBA 01/2022 - 01/2019
2	Polysaccharides (Glycans)IBA 01/2022 - 01/2021
2	Amyloid (Amyloid Fibrils)IBA 01/2022 - 01/2021
2	MicroRNAs (MicroRNA)IBA 01/2022 - 10/2020
2	Protein Isoforms (Isoforms)IBA 01/2022 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2014
2	Caveolin 1IBA 01/2022 - 01/2019
2	Adenosine Triphosphate (ATP)IBA 11/2021 - 08/2018
2	AntibodiesIBA 10/2021 - 01/2016
2	DNA (Deoxyribonucleic Acid)IBA 10/2021 - 01/2015
2	Contrast MediaIBA 01/2021 - 08/2018
2	Photosensitizing Agents (Photosensitizers)IBA 02/2020 - 01/2019
2	GraphiteIBA 01/2020 - 01/2019
2	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2019 - 01/2019
2	CytokinesIBA 01/2019 - 02/2018
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2018 - 01/2016
2	IgYIBA 01/2016 - 03/2014
1	AntigensIBA 10/2022
1	4- (2- (2- hydroxycyclohexylamino)benzothiazol- 6- yloxy)pyridine- 2- carboxylic acid methylamideIBA 10/2022
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 10/2022
1	NanovaccinesIBA 10/2022
1	Macrophage Colony-Stimulating FactorIBA 10/2022
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 10/2022
1	Collagen Type IV (Type IV Collagen)IBA 06/2022
1	hinokiflavoneIBA 04/2022
1	Tyrosine Kinase InhibitorsIBA 04/2022
1	Reactive Nitrogen SpeciesIBA 03/2022
1	Tyrosine (L-Tyrosine)FDA Link 01/2022
1	Myosin Type IIIBA 01/2022
1	GelsIBA 01/2022
1	Hyaluronic Acid (Hyaluronan)IBA 11/2021
1	Singlet OxygenIBA 11/2021
1	1- cyclohexyl- 2- (5H- imidazo(5,1- a)isoindol- 5- yl)ethanolIBA 11/2021
1	Mevalonic Acid (Mevalonate)IBA 11/2021
1	Glucose (Dextrose)FDA LinkGeneric 11/2021
1	APTIBA 10/2021
1	Scavenger Receptors (Scavenger Receptor)IBA 10/2021
1	ValinomycinIBA 10/2021
1	Cytarabine (Cytosar-U)FDA LinkGeneric 10/2021
1	hirsutanol AIBA 07/2021

Therapy/Procedure

23	Therapeutics 03/2022 - 05/2013
5	Immunotherapy 10/2022 - 02/2018
4	Lasers (Laser) 11/2021 - 02/2018
4	Precision Medicine 01/2020 - 01/2019
3	Drug Therapy (Chemotherapy) 10/2021 - 08/2018
3	Photochemotherapy (Photodynamic Therapy) 02/2020 - 02/2018
3	Photothermal Therapy 01/2020 - 02/2018
2	Catheters 10/2016 - 03/2015
1	Intravenous Administration 10/2022